11/9/2023 0 Comments Omer stocksThe company was incorporated in 1994 and is headquartered in Seattle, Washington. Omeros management will host a conference call and webcast that. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. 4, 2023- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended J, on Wednesday, Aug, before the market opens. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration longer-acting second generation antibody targeting MASP-2 and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS) and Phase II clinical trial to treat COVID-19. Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |